UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease (NCT06560606)
🩺 Plain-English Summary (8th-Grade Level)
Childhood arthritis is a chronic disabling disease. New medications called biologic therapies are now available to treat arthritis that target key biologic molecules that cause inflammation. Biologic therapies, while very effective in treating arthritis in children, may have serious side effects including infections and potentially cancers, and are very expensive and doctors don't know, which one to choose for which child. The investigators will develop tests that enable them to learn about the biology of each child's arthritis and be able to predict when and which biologic therapy to start and when to stop.
Who can join: Review the eligibility criteria below.
Location: Alberta Children's Hospital - University of Calgary — Calgary, Alberta
Age range: Not specified to 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- Alberta Children's Hospital - University of Calgary — Calgary, Alberta
- Stollery Children's Hospital — Edmonton, Alberta
- BC Children's Hospital — Vancouver, British Columbia
- Children's Hospital Health Science Centre Winnipeg — Winnipeg, Manitoba
- Janeway Children's Hospital and Rehabilitation Centre — St. John's, Newfoundland and Labrador
- IWK Health Centre — Halifax, Nova Scotia
- McMaster Children's Hospital — Hamilton, Ontario
- Children's Hospital, London Health Sciences Centre — London, Ontario
- Children's Hospital of Eastern Ontario — Ottawa, Ontario
- The Hospital for Sick Children — Toronto, Ontario
- Montréal Children's Hospital — Montreal, Quebec
- University of Saskatchewan — Saskatoon, Saskatchewan
- Amalia Children's Hospital, Radboudumc — Nijmegen, Gelderland
- Sint Maartenskinderkliniek — Boxmeer, North Brabant
- Emma Children's Hospital, Amsterdam UMC — Amsterdam, North Holland
- Willem-Alexander Children's Hospital, LUMC — Leiden, South Holland
- Sophia Children's Hospital, EMC — Rotterdam, South Holland
- Beatrix Children's Hospital, UMCG — Groningen,
- Wilhelmina Children's Hospital, UMCU — Utrecht,
📞 Contact the Study Coordinator
Phone: (416) 813-7654
Email: alexander.mosiu@sickkids.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Juvenile Idiopathic Arthritis
- An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis — Little Rock, Arkansas
- Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. — Phoenix, Arizona
- A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS) — San Miguel de Tucumán, Tucumán Province
- A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis — Rosario,
- M3-JIA: Making Mindfulness Matter for Children With JIA — Hamilton, Ontario
Explore by condition: All Juvenile Idiopathic Arthritis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.